

Javier Crespo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1555925/javier-crespo-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

6,745
citations

36
h-index

77
g-index

256
ext. papers

8,725
ext. citations

4.5
avg, IF

5.39
L-index

#	Paper	IF	Citations
218	Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients.. <i>Hepatology Communications</i> , 2022 ,	6	1
217	Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles.. <i>Hepatology</i> , 2022 ,	11.2	2
216	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review.. <i>Scientific Reports</i> , 2021 , 11, 24133	4.9	2
215	Can NAFLD overwhelm the Spanish healthcare system in the years to come?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 114, 5-9	0.9	
214	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
213	Overall clinical and economic impact of non-alcoholic fatty liver disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 113, 396-403	0.9	
212	PCSK9 and LRP5 in macrophage lipid internalization and inflammation. <i>Cardiovascular Research</i> , 2021 , 117, 2054-2068	9.9	19
211	Hepatitis C reflex testing in Spain in 2019: A story of success. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2021 , 39, 119-126	0.1	
210	Biochemical assessment of metabolic associated fatty liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021 , 2, 199-208	1.3	1
209	E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. <i>Cancer Research</i> , 2021 , 81, 2874-2887	10.1	10
208	Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. <i>Frontiers in Immunology</i> , 2021 , 12, 651728	8.4	3
207	Hepatitis C reflex testing in Spain in 2019: A story of success. <i>Enfermedades Infecciosas Y Microbiologia Clinica</i> , 2021 , 39, 119-126	0.9	7
206	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	21
205	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
204	Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFN̄and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. <i>Viruses</i> , 2021 , 13,	6.2	1
203	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021 , 41, 2076-2086	7.9	5
202	Propionate Fermentative Genes of the Gut Microbiome Decrease in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2

201	Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. <i>Scientific Reports</i> , 2021 , 11, 9819	4.9	1
200	COVID-SCORE Spain: public perceptions of key government COVID-19 control measures. <i>European Journal of Public Health</i> , 2021 , 31, 1095-1102	2.1	1
199	Triglyceride-induced cardiac lipotoxicity is mitigated by Silybum marianum. <i>Atherosclerosis</i> , 2021 , 324, 91-101	3.1	0
198	Bilirrubina: Medici3n y utilidad cl3nica en la enfermedad hep3tica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021 , 2, 362-372	1.3	
197	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. <i>United European Gastroenterology Journal</i> , 2021 , 9, 892-902	5.3	3
196	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. <i>JHEP Reports</i> , 2021 , 3, 100276	10.3	0
195	Let3 leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. <i>Journal of Hepatology</i> , 2021 , 75, 224-226	13.4	0
194	Microvesicles carrying LRP5 induce macrophage polarization to an anti-inflammatory phenotype. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 7935-7947	5.6	2
193	An Elusive Diagnosis in Noncirrhotic Chronic Portal Vein Thrombosis. <i>American Journal of Medicine</i> , 2021 , 134, e199-e200	2.4	0
192	SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. <i>Journal of Hepatology</i> , 2021 , 74, 966-967	13.4	7
191	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 1627-1633 ⁸	7.1	8
190	Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting. <i>International Journal of Drug Policy</i> , 2021 , 88, 103031	5.5	6
189	Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. <i>Journal of Hepatology</i> , 2021 , 74, 469-471	13.4	23
188	Telemedicine, time to change the paradigm of hepatitis C management: improve access and reduce costs In reference to: Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience, by P3rez Hern3ndez et al. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 113, 623-624	0.9	1
187	Valoraci3n bioqu3mica en la enfermedad hep3tica grasa asociada a la disfunci3n metab3lica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021 , 2, 209-219	1.3	
186	National digestive disease specialists survey on cardiovascular risk management in non-alcoholic fatty liver disease in spanish hospitals. <i>Liver International</i> , 2021 , 41, 1243-1253	7.9	0
185	Measurement and clinical usefulness of bilirubin in liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021 , 2, 352-361	1.3	1
184	Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH. <i>Journal of Hepatology</i> , 2021 , 75, 34-45	13.4	4

183	Non-malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors. <i>Hepatology Research</i> , 2021 , 51, 1064-1072	5.1	0
182	HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?. <i>Journal of Hepatology</i> , 2021 , 75, 486-487	13.4	2
181	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
180	Anti-epileptic drugs and hepatitis C therapy: Real-world experience. <i>Journal of Hepatology</i> , 2021 , 75, 984-985	13.4	0
179	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. <i>Molecular Metabolism</i> , 2021 , 53, 101275	8.8	2
178	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.. <i>Biomedicines</i> , 2021 , 10,	4.8	2
177	Is Routine Prophylaxis Against Needed in Liver Transplantation? A Retrospective Single-Centre Experience and Current Prophylaxis Strategies in Spain. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
176	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 332-347	0.9	6
175	A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
174	Bone mineral density and trabecular bone score in treatment-naïve patients with non-cirrhotic hepatitis C virus infection. <i>Archives of Osteoporosis</i> , 2020 , 15, 72	2.9	0
173	Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020 , 21, 472	2.8	5
172	Update on epidemiology of hepatitis B in a low-endemic European country: There is still much to do. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1261-1265	3.4	0
171	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020 , 40, 2182-2193	7.9	6
170	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020 , 73, 17-25	13.4	26
169	Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. <i>Nature Communications</i> , 2020 , 11, 3360	17.4	34
168	The Mediterranean diet decreases prothrombotic microvesicle release in asymptomatic individuals at high cardiovascular risk. <i>Clinical Nutrition</i> , 2020 , 39, 3377-3384	5.9	12
167	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. <i>Cell Metabolism</i> , 2020 , 31, 605-622.e10	24.6	24
166	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. <i>Gastroenterology</i> , 2020 , 159, 521-533.e9	13.3	33

165	Strategy for the Elimination of Hepatitis C in Cantabria. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 565-570	0.9	2
164	COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 389-396	0.9	13
163	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 397-411	0.9	5
162	Biopsy for hepatocellular carcinoma: only occasionally. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 666-667	0.9	
161	Digestive units in the National Health System of the 21st century. Organizational and management standards for a patient-centered service. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 144-149	0.9	2
160	Principles for implementing a population screening strategy for hepatitis C in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 64-70	0.9	2
159	Author's answer to: "Effect of adacolumn in ulcerative colitis with COVID-19". <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 511-512	0.9	0
158	Relationship between gastroenterologists and hospital pharmacists: the results of a national survey. The CONDIFA study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 675-681	0.9	
157	Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 778-783	0.9	
156	In reply to: Confirmation of antibodies against hepatitis C virus by recombinant immunoblot: Is it really an improvement to abandon it?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020 , 38, 95	0.9	2
155	Liquid Biopsies: Microvesicles in Cardiovascular Disease. <i>Antioxidants and Redox Signaling</i> , 2020 , 33, 645-662	0.9	12
154	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020 , 174, 104694	10.8	20
153	Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 360-370	3.4	19
152	COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102683	13.6	2
151	Congestive Hepatopathy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
150	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46
149	Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 267-271	2.2	6
148	Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. <i>Annals of Hepatology</i> , 2019 , 18, 236-239	3.1	1

147	Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 95, 109677	5.5	14
146	MicroRNA-145 Regulates the Differentiation of Adipose Stem Cells Toward Microvascular Endothelial Cells and Promotes Angiogenesis. <i>Circulation Research</i> , 2019 , 125, 74-89	15.7	27
145	Liquid Biopsy of Extracellular Microvesicles Predicts Future Major Ischemic Events in Genetically Characterized Familial Hypercholesterolemia Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 1172-1181	9.4	19
144	HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?. <i>Current Hepatology Reports</i> , 2019 , 18, 259-267	1	2
143	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019 , 7, 825-837	5.3	11
142	LOXL2-A New Target in Antifibrogenic Therapy?. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	31
141	PS-200-The combination of HEPamet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD. <i>Journal of Hepatology</i> , 2019 , 70, e133-e134	13.4	3
140	Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2019 , 37, 231-238	0.1	
139	Liquid Biopsy of Extracellular Microvesicles Maps Coronary Calcification and Atherosclerotic Plaque in Asymptomatic Patients With Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 945-955	9.4	26
138	Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. <i>Digestive and Liver Disease</i> , 2019 , 51, 95-103	3.3	8
137	Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
136	miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. <i>Molecular Metabolism</i> , 2019 , 29, 40-54	8.8	17
135	High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. <i>Journal of Hepatology</i> , 2019 , 71, 876-888	13.4	8
134	FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection. <i>Journal of Hepatology</i> , 2019 , 70, e493-e494	13.4	4
133	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 579-592	0.1	2
132	An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 275-282	0.9	28
131	The efficiency of several one-step testing strategies for the diagnosis of hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 10-16	0.9	9
130	Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 731-737	0.9	2

129	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 862-873	0.9	4
128	Geographic analysis and estimation of hepatitis C cases in migrant populations living in Spain: is a country-based screening strategy appropriate?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 615-625	0.9	2
127	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 579-592	0.9	13
126	Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 231-238	0.9	17
125	Improved Health Outcomes from Hepatitis C Treatment Scale-Up in SpainB Prisons: A Cost-Effectiveness Study. <i>Scientific Reports</i> , 2019 , 9, 16849	4.9	10
124	Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. <i>Cells</i> , 2019 , 8,	7.9	7
123	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	4.0	425
122	Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis. <i>Data in Brief</i> , 2019 , 27, 104415	1.2	1
121	Stem cells from human cardiac adipose tissue depots show different gene expression and functional capacities. <i>Stem Cell Research and Therapy</i> , 2019 , 10, 361	8.3	5
120	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 54-64.e1	6.9	31
119	Oxidized Low-Density Lipoprotein Receptor in Lymphocytes Prevents Atherosclerosis and Predicts Subclinical Disease. <i>Circulation</i> , 2019 , 139, 243-255	16.7	15
118	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 328-349	0.9	30
117	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018 , 68, 940-948	13.4	12
116	A Rare But Recognizable Cholestatic Liver Disease. <i>Gastroenterology</i> , 2018 , 155, e17-e19	13.3	
115	Reply to the letter by Dr. Ulas to the manuscript entitled: "Silybum marianum provides cardioprotection and limits adverse remodeling post-myocardial infarction by mitigating oxidative stress and reactive fibrosis". <i>International Journal of Cardiology</i> , 2018 , 270, 78	3.2	1
114	Diet, microparticles and atherothrombosis. <i>Frontiers in Bioscience - Landmark</i> , 2018 , 23, 432-457	2.8	14
113	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018 , 69, 896-904	13.4	550
112	Silybum marianum provides cardioprotection and limits adverse remodeling post-myocardial infarction by mitigating oxidative stress and reactive fibrosis. <i>International Journal of Cardiology</i> , 2018 , 270, 28-35	3.2	15

111	Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. <i>World Journal of Clinical Cases</i> , 2018 , 6, 611-623	1.6	2
110	Endoscopy and sedation: an inseparable binomial for the gastroenterologist. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018 , 110, 250-252	0.9	3
109	Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. <i>Annals of Hepatology</i> , 2018 , 17, 0-10	3.1	
108	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018 , 110, 641-649	0.9	2
107	Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. <i>Oncotarget</i> , 2018 , 9, 30869-30882	3.3	8
106	Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 3655-3667	6.9	15
105	MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. <i>Cell Death and Disease</i> , 2018 , 9, 958	9.8	28
104	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1260-1270	6.1	43
103	Metabolic effects of reduced growth hormone action in fatty liver disease. <i>Hepatology International</i> , 2018 , 12, 474-481	8.8	14
102	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease 2018 ,		3
101	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 328-349	0.1	1
100	Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. <i>Hepatology Communications</i> , 2018 , 2, 807-820	6	64
99	Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1639-1648	0.7	43
98	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 784-793	4	48
97	Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2017 , 152, 1449-1461.e7	13.3	139
96	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 945-949.e1	6.9	18
95	Influence of anti-TNF therapy on bone metabolism in patients with inflammatory bowel disease. <i>European Journal of Internal Medicine</i> , 2017 , 39, e33-e34	3.9	2
94	Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. <i>Medicina Clínica</i> , 2017 , 148, 277-282	1	23

93	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. <i>Hepatology</i> , 2017 , 65, 1810-1822	11.2	64
92	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017 , 66, 1138-1148	13.4	131
91	Hepatic p63 regulates steatosis via IKK β /ER stress. <i>Nature Communications</i> , 2017 , 8, 15111	17.4	32
90	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017 , 37, 1823-1832	7.9	8
89	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica</i> , 2017 , 149, 61-71	1	13
88	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2017 , 106, 55-67	5.8	34
87	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2017 , 66, 718-723	13.4	80
86	Ascites: Treatment, Complications, and Prognosis 2017 ,		1
85	Resistance to hepatitis C virus. Implications and therapeutic options. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017 , 40, 484-494	0.1	
84	Resistance to hepatitis C virus. Implications and therapeutic options. <i>Gastroenterología Y Hepatología</i> , 2017 , 40, 484-494	0.9	1
83	Deregulated neddylation in liver fibrosis. <i>Hepatology</i> , 2017 , 65, 694-709	11.2	28
82	The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. <i>Nature Communications</i> , 2017 , 8, 2068	17.4	45
81	AA Amyloidosis Associated with Jugular Paraganglioma as a Rare Cause of Chronic Diarrhea. <i>ACG Case Reports Journal</i> , 2017 , 4, e100	0.6	1
80	A morphological method for ammonia detection in liver. <i>PLoS ONE</i> , 2017 , 12, e0173914	3.7	18
79	Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017 , 109, 619-626	0.9	4
78	Gastroenterology, a historical specialty with a great future. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017 , 109, 611-613	0.9	
77	Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017 , 109, 17-25	0.9	12
76	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. <i>Psychopharmacology</i> , 2016 , 233, 3947-3952	4.7	26

75	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016 , 6, 31421	4.9	22
74	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 779-89	3	20
73	Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the International Consensus Diagnostic Criteria: A multi-centre study. <i>Pancreatology</i> , 2016 , 16, 382-90	3.8	22
72	Microparticle Shedding from Neural Progenitor Cells and Vascular Compartment Cells Is Increased in Ischemic Stroke. <i>PLoS ONE</i> , 2016 , 11, e0148176	3.7	41
71	Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016 , 108, 421-30	0.9	2
70	CD142+/CD61+, CD146+ and CD45+ microparticles predict cardiovascular events in high risk patients following a Mediterranean diet supplemented with nuts. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 103-14	7	22
69	Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	17
68	Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1662-1666.e1	6.9	34
67	CD3(+)/CD45(+) and SMA-(+) circulating microparticles are increased in individuals at high cardiovascular risk who will develop a major cardiovascular event. <i>International Journal of Cardiology</i> , 2016 , 208, 147-9	3.2	40
66	Computerized Physician Order Entry-Based System Improves Hepatitis B Virus Screening in Patients Undergoing Chemotherapy. <i>Journal of Clinical Oncology</i> , 2016 , 34, 290	2.2	1
65	NS5A Resistance: Clinical Implications and Treatment Possibilities. <i>AIDS Reviews</i> , 2016 , 18, 15-22	1.5	4
64	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015 , 68, 56-60	14.5	9
63	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. <i>Liver International</i> , 2015 , 35, 1775	7.9	
62	Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice. <i>Liver International</i> , 2015 , 35, 401-8	7.9	15
61	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015 , 35, 90-100	7.9	12
60	Roflumilast-induced Local Vascular Injury Is Associated with a Coordinated Proteome and Microparticle Change in the Systemic Circulation in Pigs. <i>Toxicologic Pathology</i> , 2015 , 43, 569-80	2.1	1
59	The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?. <i>BioMed Research International</i> , 2015 , 2015, 386186	3	15
58	Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study. <i>PLoS ONE</i> , 2015 , 10, e0122613	3.7	1

57	Circulating endothelial progenitor cells and the risk of vascular events after ischemic stroke. <i>PLoS ONE</i> , 2015 , 10, e0124895	3.7	20
56	The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2015 , 2015, 319745	3	10
55	Plasma betatrophin levels in patients with liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10662-8	5.6	12
54	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015 , 14, 477-486	3.1	1
53	Colorectal adenomas contain multiple somatic mutations that do not coincide with synchronous adenocarcinoma specimens. <i>PLoS ONE</i> , 2015 , 10, e0119946	3.7	7
52	Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. <i>United European Gastroenterology Journal</i> , 2015 , 3, 284-93	5.3	4
51	NOR-1 modulates the inflammatory response of vascular smooth muscle cells by preventing NFB activation. <i>Journal of Molecular and Cellular Cardiology</i> , 2015 , 80, 34-44	5.8	32
50	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015 , 62, 311-6	13.4	11
49	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015 , 62, 1246-55	13.4	19
48	miR-17 and -20a Target the Neuron-Derived Orphan Receptor-1 (NOR-1) in Vascular Endothelial Cells. <i>PLoS ONE</i> , 2015 , 10, e0141932	3.7	4
47	Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11016-26	5.6	26
46	Binge drinking: Burden of liver disease and beyond. <i>World Journal of Hepatology</i> , 2015 , 7, 2703-15	3.4	36
45	Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 65-73	4.6	31
44	HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model. <i>International Journal of Cardiology</i> , 2014 , 175, 528-38	3.2	22
43	Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project. <i>Hepatology</i> , 2014 , 60, 106-13	11.2	21
42	Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 23163-78	6.3	47
41	Vitamin D deficiency in chronic liver disease. <i>World Journal of Hepatology</i> , 2014 , 6, 901-15	3.4	63
40	Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 45, 109-16	12.3	48

39	Endothelial progenitor cells in acute ischemic stroke. <i>Brain and Behavior</i> , 2013 , 3, 649-55	3.4	32
38	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. <i>Gastroenterología Y Hepatología</i> , 2013 , 36, 555-64	0.9	1
37	Long-term survival after liver transplantation for alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2013 , 19, 9198-208	5.6	42
36	Chemoprophylaxis with isoniazid in liver transplant recipients. <i>Liver Transplantation</i> , 2012 , 18, 1110-7	4.5	26
35	Nonalcoholic Fatty Liver Disease: A Pathological View 2012 ,		5
34	Epidemiology of intrafamilial inflammatory bowel disease throughout Europe. <i>Annals of Gastroenterology</i> , 2012 , 25, 188-192	2.2	3
33	Fibulin-5 is up-regulated by hypoxia in endothelial cells through a hypoxia-inducible factor-1 (HIF-1)-dependent mechanism. <i>Journal of Biological Chemistry</i> , 2011 , 286, 7093-103	5.4	49
32	Assessment of health sciences and science and technology librarian e-science educational needs to develop an e-science web portal for librarians. <i>Journal of the Medical Library Association: JMLA</i> , 2011 , 99, 153-6	1.4	5
31	Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. <i>Liver International</i> , 2010 , 30, 1137-42	7.9	69
30	El neuron-derived orphan receptor-1 previene la apoptosis inducida por la hipoxia en las células endoteliales vasculares. <i>Clínica E Investigación En Arteriosclerosis</i> , 2010 , 22, 39-48	1.4	
29	The hypoxia-inducible factor 1/NOR-1 axis regulates the survival response of endothelial cells to hypoxia. <i>Molecular and Cellular Biology</i> , 2009 , 29, 5828-42	4.8	50
28	Coagulation Disorders in Acute Lung Injury. <i>Current Respiratory Medicine Reviews</i> , 2009 , 5, 149-159	0.3	1
27	Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. <i>Obesity Surgery</i> , 2007 , 17, 1374-80	3.7	211
26	Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006 , 43, 72-80	11.2	41
25	NOR-1 is involved in VEGF-induced endothelial cell growth. <i>Atherosclerosis</i> , 2006 , 184, 276-82	3.1	44
24	Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. <i>Gastroenterology</i> , 2006 , 131, 451-60	13.3	311
23	Increased expression of Ob-Rb and its relationship with the overexpression of TGF-beta1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2006 , 26, 1065-71	7.9	32
22	Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. <i>Obesity Surgery</i> , 2005 , 15, 442-6	3.7	84

21	Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. <i>Cardiovascular Research</i> , 2005 , 67, 333-41	9.9	20
20	Sleep Apnea Obstructive Syndrome: A New Complication Previously Undescribed in Cirrhotic Patients with Ascites: Response to Drs. Golpe and Mateos. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1423-1423	0.7	
19	Involvement of neuron-derived orphan receptor-1 (NOR-1) in LDL-induced mitogenic stimulus in vascular smooth muscle cells: role of CREB. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 697-702	9.4	51
18	Serum immunological profile in patients with chronic autoimmune cholestasis. <i>American Journal of Gastroenterology</i> , 2004 , 99, 2150-7	0.7	17
17	Sleep apnea obstructive syndrome: a new complication previously undescribed in cirrhotic patients with ascites. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2815-6	0.7	23
16	Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. <i>Liver Transplantation</i> , 2003 , 9, 916-20	4.5	37
15	Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. <i>Journal of Biological Chemistry</i> , 2003 , 278, 5509-12	5.4	1255
14	Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 1604-10	4	58
13	Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis?. <i>Obesity Surgery</i> , 2001 , 11, 254-7	3.7	68
12	Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. <i>Hepatology</i> , 2001 , 34, 1158-63	11.2	468
11	Dendroaspis natriuretic peptide in hepatic cirrhosis. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2726-9	4	
10	Dendroaspis natriuretic peptide in hepatic cirrhosis. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2726-729		
9	Hepatitis crónica por VHC en la población usuaria de drogas por vía parenteral. Motivos para no iniciar el tratamiento antiviral. <i>Revista De Psicología De La Salud</i> , 2001 , 13, 399	1	2
8	Involvement of the fas system in hepatitis C virus recurrence after liver transplantation. <i>Liver Transplantation</i> , 2000 , 6, 562-9	4.5	16
7	Granulocyte elastase in cirrhotic patients with spontaneous bacterial peritonitis. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 1985-9	4	3
6	Severe clinical course of de novo hepatitis B infection after liver transplantation. <i>Liver Transplantation</i> , 1999 , 5, 175-83		42
5	Adrenomedullin in liver transplantation and its relationship with vascular complications. <i>Liver Transplantation</i> , 1999 , 5, 485-90		6
4	Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial. <i>Gastrointestinal Endoscopy</i> , 1999 , 49, 417-23	5.2	82

3	Alcoholic recidivism after liver transplantation for alcoholic cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 1998 , 26, 204-6	3	44
2	Endothelin-1 and vascular complications in liver transplantation. <i>Transplantation</i> , 1995 , 59, 1748-51	1.8	8
1	Targeting Hepatic Glutaminase 1 Ameliorates Non-Alcoholic Steatohepatitis by Restoring Disrupted Hepatic Very-Low Density Lipoproteins Triglyceride Assembly. <i>SSRN Electronic Journal</i> ,	1	1